ALLO - Allogene Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.43
DETAILS
HIGH:
$9.00
LOW:
$3.85
MEDIAN:
$6.42
CONSENSUS:
$6.43
UPSIDE:
221.50%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Revenue | 0 | 0.0 | 0.1 | 0.2 | 114.1 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.4 | 0 | 0 | 14.3 | 0 | 11.5 | 5.0 | 0 | 0 |
| Gross Profit | (12.4) | 0.0 | 0.1 | (14.1) | 114.1 | (11.5) | (5.0) | (1.5) | 0 |
| Operating Expenses | |||||||||
| R&D Expenses | 150.2 | 192.3 | 242.9 | 256.4 | 220.2 | 193.0 | 144.5 | 151.9 | 0 |
| SG&A Expenses | 56.8 | 65.2 | 71.7 | 79.3 | 74.1 | 65.3 | 57.5 | 41.0 | 0.0 |
| Other Expenses | (12.4) | 15.7 | 13.2 | (14.3) | 0 | (11.5) | 0 | 0 | 0 |
| Operating Expenses | 194.6 | 273.2 | 327.8 | 321.4 | 294.3 | 246.7 | 202.0 | 192.8 | 0.0 |
| Operating Income | |||||||||
| Operating Income | (206.9) | (273.2) | (327.7) | (335.5) | (180.2) | (258.2) | (202.0) | (192.8) | (0.0) |
| Interest Expense | 1.1 | 0.2 | 0 | 0 | 0 | 0 | 0 | 3.4 | 0 |
| Interest Income | 19.3 | 20.2 | 18.3 | 4.6 | 1.7 | 9.2 | 17.4 | 5.8 | 0 |
| Profitability | |||||||||
| EBITDA | (194.6) | (243.3) | (313.1) | (321.2) | (169.7) | (238.7) | (179.9) | (206.8) | 0.0 |
| EBIT | (206.9) | (257.0) | (327.3) | (335.5) | (180.2) | (250.2) | (184.9) | (208.3) | (0.0) |
| Income Before Tax | (190.9) | (257.1) | (327.3) | (340.4) | (182.1) | (250.2) | (184.9) | (211.6) | (0.0) |
| Income Tax Expense | 0 | 0.4 | 0 | 0 | 0 | 0 | (0.3) | (0.1) | (0.0) |
| Net Income | (190.9) | (257.6) | (327.3) | (340.4) | (182.1) | (250.2) | (184.6) | (211.5) | (0.0) |
| Per Share Data | |||||||||
| EPS (Basic) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.08 | -1.83 | -2.36 | – |
| EPS (Diluted) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.08 | -1.83 | -2.36 | – |
| Shares Outstanding | 220.6 | 194.8 | 156.9 | 143.1 | 135.8 | 120.4 | 101.1 | 89.7 | 44.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Assets | |||||||||
| Cash & Cash Equivalents | 51.7 | 75.2 | 83.2 | 61.9 | 173.3 | 183.4 | 175.1 | 721.4 | 0 |
| Short-Term Investments | 198.5 | 217.3 | 365.5 | 455.4 | 284.0 | 644.6 | 355.4 | 0 | 0 |
| Net Receivables | 1.5 | 1.9 | 1.7 | 0 | 0 | 0 | 2.4 | 3.1 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (262.0) | 0 |
| Other Current Assets | 6.0 | 9.0 | 0 | 11.5 | 0 | 0 | (2.4) | 0 | 0 |
| Total Current Assets | 257.7 | 303.4 | 459.1 | 528.8 | 471.3 | 845.1 | 544.6 | 468.0 | 0 |
| Non-Current Assets | |||||||||
| Property, Plant & Equipment | 112.7 | 131.3 | 163.2 | 196.4 | 181.0 | 160.1 | 100.9 | 41.6 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.8 | 0 |
| Long-Term Investments | 8.0 | 80.7 | 3.6 | 76.5 | 382.4 | 207.9 | 63.2 | 262.0 | 0 |
| Other Non-Current Assets | 37.4 | 33.4 | 16.9 | 19.9 | 16.1 | 14.6 | 8.9 | 1.5 | 0 |
| Total Non-Current Assets | 158.2 | 245.3 | 183.7 | 292.8 | 579.5 | 382.7 | 173.2 | 305.9 | 0 |
| Total Assets | 415.9 | 548.7 | 642.8 | 821.6 | 1,050.8 | 1,227.8 | 717.8 | 773.9 | 0 |
| Current Liabilities | |||||||||
| Account Payables | 4.3 | 5.4 | 5.9 | 13.9 | 10.3 | 10.4 | 9.2 | 12.3 | 0 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0.1 | 0.1 | 0.2 | 39.0 | 0 | 0 | 0 |
| Other Current Liabilities | 28.2 | 12.1 | 11.7 | 17.9 | 16.1 | 13.0 | 12.4 | 5.2 | 0 |
| Total Current Liabilities | 32.5 | 35.5 | 37.1 | 53.7 | 47.9 | 94.3 | 33.1 | 29.5 | 0.0 |
| Non-Current Liabilities | |||||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 15.8 | 7.8 | 5.2 | 5.8 | 7.8 | 3.1 | 4.4 | 6.8 | 0 |
| Total Non-Current Liabilities | 90.8 | 91.0 | 93.5 | 101.0 | 77.7 | 53.9 | 55.7 | 41.2 | 0 |
| Total Liabilities | 123.4 | 126.5 | 130.6 | 154.7 | 125.6 | 148.2 | 88.8 | 70.7 | 0.0 |
| Stockholders' Equity | |||||||||
| Common Stock | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Retained Earnings | (2,010.7) | (1,819.8) | (1,562.2) | (1,235.0) | (894.6) | (646.3) | (396.1) | (211.5) | (0.0) |
| Accumulated Other Comprehensive Income | 0.3 | (0.1) | (1.0) | (9.9) | (2.6) | 0.3 | 1.1 | 0.3 | (0.0) |
| Total Stockholders' Equity | 292.5 | 422.2 | 512.2 | 666.9 | 925.2 | 1,079.6 | 629.0 | 703.2 | (0.0) |
| Total Liabilities & Equity | 415.9 | 548.7 | 642.8 | 821.6 | 1,050.8 | 1,227.8 | 717.8 | 773.9 | 0 |
| Debt Metrics | |||||||||
| Total Debt | 75.0 | 90.8 | 95.1 | 101.1 | 73.1 | 53.8 | 53.0 | 34.5 | 0 |
| Net Debt | 23.4 | 15.5 | 12.0 | 39.2 | (100.2) | (129.6) | (122.1) | (686.9) | 0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | (190.9) | (257.6) | (327.3) | (332.6) | (257.0) | (250.2) | (184.6) | (211.5) | (0.0) |
| Depreciation & Amortization | 12.4 | 13.6 | 14.2 | 14.3 | 10.5 | 7.6 | 5.0 | 1.5 | 0 |
| Stock-Based Compensation | 37.6 | 51.7 | 66.0 | 83.6 | 80.8 | 65.3 | 46.1 | 18.6 | 0 |
| Change in Working Capital | (10.9) | (24.8) | (15.3) | 3.7 | (32.1) | 53.9 | (6.9) | 12.1 | 0.0 |
| Other Non-Cash Items | 2.5 | 16.3 | 24.7 | 2.4 | 2.6 | 4.0 | 3.4 | 134.8 | 0 |
| Operating Cash Flow | (149.2) | (200.3) | (237.7) | (220.5) | (184.8) | (115.1) | (137.3) | (44.7) | 0 |
| Investing Activities | |||||||||
| Capital Expenditure | (0.4) | (0.7) | (1.5) | (5.2) | (21.4) | (66.0) | (50.8) | (3.2) | 0 |
| Acquisitions | 0 | 0 | 0 | (111.3) | (17.7) | 439.2 | (5.1) | 0 | 0 |
| Purchases of Investments | (138.3) | (361.5) | (438.6) | (248.1) | (525.6) | (1,037.6) | (252.6) | (649.3) | 0 |
| Sales/Maturities of Investments | 234.2 | 437.9 | 603.4 | 359.5 | 728.4 | 598.4 | 472.6 | 21.8 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 111.3 | 0 | (439.2) | 0 | (2.1) | 0 |
| Investing Cash Flow | 95.6 | 75.7 | 163.3 | 106.2 | 163.7 | (505.1) | 164.1 | (632.8) | 0 |
| Financing Activities | |||||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 116.8 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.9 | 2.3 | 4.6 | 0 | 0 | 11.7 | 4.7 | 654.3 | 0 |
| Financing Cash Flow | 30.2 | 116.7 | 95.7 | 3.0 | 12.0 | 633.6 | 59.0 | 771.2 | 0 |
| Cash Position | |||||||||
| Net Change in Cash | (23.5) | (7.9) | 21.3 | (111.4) | (9.2) | 13.4 | 85.7 | 93.7 | 0 |
| Cash at Beginning | 85.5 | 93.4 | 72.2 | 183.6 | 192.8 | 179.4 | 93.7 | 0 | 0 |
| Cash at End | 62.0 | 85.5 | 93.4 | 72.2 | 183.6 | 192.8 | 179.4 | 93.7 | 0 |
| Free Cash Flow | (149.6) | (201.0) | (239.2) | (225.7) | (206.3) | (181.1) | (188.1) | (47.9) | 0 |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0 | 0.0 | 0.1 | 0.2 | 114.1 | 0 | 0 | 0 | 0 |
| Gross Profit | (12.4) | 0.0 | 0.1 | (14.1) | 114.1 | (11.5) | (5.0) | (1.5) | 0 |
| Operating Income | (206.9) | (273.2) | (327.7) | (335.5) | (180.2) | (258.2) | (202.0) | (192.8) | (0.0) |
| Net Income | (190.9) | (257.6) | (327.3) | (340.4) | (182.1) | (250.2) | (184.6) | (211.5) | (0.0) |
| EPS (Diluted) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.08 | -1.83 | -2.36 | – |
| Balance Sheet | |||||||||
| Cash & Equivalents | 51.7 | 75.2 | 83.2 | 61.9 | 173.3 | 183.4 | 175.1 | 721.4 | 0 |
| Total Assets | 415.9 | 548.7 | 642.8 | 821.6 | 1,050.8 | 1,227.8 | 717.8 | 773.9 | 0 |
| Total Debt | 75.0 | 90.8 | 95.1 | 101.1 | 73.1 | 53.8 | 53.0 | 34.5 | 0 |
| Stockholders' Equity | 292.5 | 422.2 | 512.2 | 666.9 | 925.2 | 1,079.6 | 629.0 | 703.2 | (0.0) |
| Cash Flow | |||||||||
| Operating Cash Flow | (149.2) | (200.3) | (237.7) | (220.5) | (184.8) | (115.1) | (137.3) | (44.7) | 0 |
| Capital Expenditure | (0.4) | (0.7) | (1.5) | (5.2) | (21.4) | (66.0) | (50.8) | (3.2) | 0 |
| Free Cash Flow | (149.6) | (201.0) | (239.2) | (225.7) | (206.3) | (181.1) | (188.1) | (47.9) | 0 |